Introduction
Introduction Statistics Contact Development Disclaimer Help
Return Create A Forum - Home
---------------------------------------------------------
MS Speaks
https://msspeaks.createaforum.com
---------------------------------------------------------
*****************************************************
Return to: TECFIDERA (dimethyl fumarate, BG-12, Fumaderm)
*****************************************************
#Post#: 4220--------------------------------------------------
(Abst.) Discontinuation of dimethyl fumarate in MS --a nationwid
e study [Denmark]
By: agate Date: November 15, 2023, 1:45 am
---------------------------------------------------------
From PubMed (November 14, 2023)--"Discontinuation of dimethyl
fumarate in multiple sclerosis--a nationwide study":
https://pubmed.ncbi.nlm.nih.gov/37956521/
The authors conclude that
[quote]In this population-based study, we found major
differences between the MS clinics in rates and reason for
discontinuation of DMF. Our results suggest that management
strategies during DMF treatment can reduce discontinuation
rates.[/quote]
Of the experimental subjects, 54.5% stopped taking Tecfidera
because of adverse events, and 26.1% stopped taking it because
of "active disease." It looks as if Tecfidera hasn't gone over
very well, all in all. And the solution to this, the authors
suggest, might be better "management strategies."
The MS clinics are probably being told, in effect, that they
need to manage their patients on Tecfidera better. I wonder what
this means though.
When I've been taking an MS drug (Avonex, Copaxone, Glatopa),
the prescribing neurologist just prescribed it and ordered some
standard lab work and had very little to say otherwise on the
topic. When I wanted to stop the Avonex and later the Copaxone,
there was no attempt at persuading me to continue. Would these
better management strategies mean that patients wanting to stop
an MS drug (like Tecifidera) will be more actively encouraged to
stay on it?
*****************************************************
You are viewing proxied material from gopher.createaforum.com. The copyright of proxied material belongs to its original authors. Any comments or complaints in relation to proxied material should be directed to the original authors of the content concerned. Please see the disclaimer for more details.